The impact of contraception on health-related quality of life and the efficacy of the contraceptive method in reproductive-aged women is an important determinant in contraception choice and adherence with contraception methods. The primary goal of this study is to assess the quality of life of women using E4/DRSP, using the questionnaire developed by the Sociedad Española de Contracepción quality of life (SEC-QoL). This study is an observational, prospective, single-arm, international multi-centre, open-label Phase 4 study to assess QoL using the SEC-QoL, adherence, and clinical safety and tolerability of E4/DRSP in women aged 16 or older without contraindications for E4/DRSP and to linguistically validate the SEC-QoL. Participants must be prescribed E4/DRSP by a healthcare professional and must initiate E4/DRSP up to 4 weeks after the baseline visit. Study assessments, including the SEC-QoL, will be taken at baseline, 3-months, and 6-months. After the baseline visit, study assessments will be remotely administered. The Spanish version of the SEC-QoL questionnaire will be translated through a process that ensures linguistic validity into English. The English version will then be translated through the same process that ensures linguistic validity into the appropriate target languages including German, French, Hungarian, Italian, and Polish. Participant-reported data on demographics, medical history, concomitant medications, contraception use, and the SEC-QoL questionnaire will be collected at the baseline visit via an electronic case report form (eCRF). During subsequent study assessments at 3- and 6-months, the SEC-QoL questionnaire, pregnancy information, concomitant medications, study status, other forms of contraception utilised, and adherence, will be collected using the participant-reported ePRO module. AEs will be reported at any time by the participant using the ePRO module.